RESEARCH DASHBOARD
-
RELEASE DATE
-
Executive Pool
3309 -
PRICE
US$ -
EXPERT INPUTS
596 -
Companies
0 -
DATA Tables
125 -
Pages
219 -
Edition
1
WHAT'S BEHIND OUR DATA?
-
DOMAIN TRANSCRIPTS
140857226 -
BRANDS TRACKED
6080276 -
FEATURED COMPANIES
1729341 -
TOPICS COVERED
22574 -
MARKET SEGMENTS
82719 -
KEY INDUSTRIES
91 -
CURATION TEAM
1574 -
DECISION MAKERS
4761909
EXECUTIVES TRACKED (368)
-
CXO
50 -
VICE PRESIDENT
29 -
DIRECTOR
132 -
MANAGER
75MARKETING
82
EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
-
EDITION 1
-
TABLES 125
-
REGIONS
-
SEGMENTS
-
PAGES 219
-
US$
-
MCP11004
-
JOIN OUR PANEL
SELECT LICENSE TYPE
HIGHLIGHTS & REPORT INDEX
SCOPE OF STUDY
The report analyzes the Chemotherapy-induced Nausea and Vomiting Drugs market by the following Segments, and Geographic Regions/Countries:
Segments:
.
Geographic Regions/Countries:
.
SELECT PLAYERS
AI INTEGRATIONS
We’re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| Global Economic Update |
| Chemotherapy-induced Nausea and Vomiting Drugs – Global Key Competitors Percentage Market Share in 2024 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 23 Players Worldwide in 2024 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Rising Global Cancer Incidence Propels Demand for Chemotherapy-Induced Nausea and Vomiting Drugs |
| Advancements in Anti-Emetic Drug Formulations Drive Adoption of Next-Generation CINV Therapies |
| Increasing Use of Combination Chemotherapy Spurs Growth in the Anti-Emetic Drug Market |
| Growing Demand for Oral and Non-Invasive Drug Delivery Systems Generates Opportunities for Innovation |
| Here`s How Extended-Release and Long-Acting Formulations Sustain Market Growth |
| Expanding Role of Digital Health Tools in Managing CINV Drives Adoption of Patient-Centered Solutions |
| Focus on Reducing Hospital Readmissions Due to CINV Strengthens Demand for Effective Treatments |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030 |
| World Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Serotonin Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Neurokinin NK1 Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Dopamine Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Benzodiazepine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E) |
| USA Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| USA 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Canada 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| JAPAN |
| Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E) |
| Japan Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Japan 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| CHINA |
| Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E) |
| China Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| China 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| EUROPE |
| Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E) |
| Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| FRANCE |
| Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E) |
| France Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| France 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| GERMANY |
| Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E) |
| Germany Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Germany 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Italy 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| UNITED KINGDOM |
| Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E) |
| UK Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| UK 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| ASIA-PACIFIC |
| Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030 |